{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T16:04:42Z","timestamp":1791389082618,"version":"4.3.3"},"reference-count":160,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2021,11,23]],"date-time":"2021-11-23T00:00:00Z","timestamp":1637625600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceutics"],"abstract":"<jats:p>The review includes studies dated 2011\u20132021 presenting the newest information on voriconazole (VCZ), mycophenolic acid (MPA), and vancomycin (VAN) therapeutic drug monitoring (TDM) in children. The need of TDM in pediatric patients has been emphasized by providing the information on the differences in the drugs pharmacokinetics. TDM of VCZ should be mandatory for all pediatric patients with invasive fungal infections (IFIs). Wide inter- and intrapatient variability in VCZ pharmacokinetics cause achieving and maintaining therapeutic concentration during therapy challenging in this population. Demonstrated studies showed, in most cases, VCZ plasma concentrations to be subtherapeutic, despite the updated dosages recommendations. Only repeated TDM can predict drug exposure and individualizing dosing in antifungal therapy in children. In children treated with mycophenolate mofetil (MMF), similarly as in adult patients, the role of TDM for MMF active form, MPA, has not been well established and is undergoing continued debate. Studies on the MPA TDM have been carried out in children after renal transplantation, other organ transplantation such as heart, liver, or intestine, in children after hematopoietic stem cell transplantation or cord blood transplantation, and in children with lupus, nephrotic syndrome, Henoch-Sch\u00f6nlein purpura, and other autoimmune diseases. MPA TDM is based on the area under the concentration\u2013time curve; however, the proposed values differ according to the treatment indication, and other approaches such as pharmacodynamic and pharmacogenetic biomarkers have been proposed. VAN is a bactericidal agent that requires TDM to prevent an acute kidney disease. The particular group of patients is the pediatric one. For this group, the general recommendations of the dosing may not be valid due to the change of the elimination rate and volume of distribution between the subjects. The other factor is the variability among patients that concerns the free fraction of the drug. It may be caused by both the patients\u2019 population and sample preconditioning. Although VCZ, MMF, and VAN have been applied in pediatric patients for many years, there are still few issues to be solve regarding TDM of these drugs to ensure safe and effective treatment. Except for pharmacokinetic approach, pharmacodynamics and pharmacogenetics have been more often proposed for TDM.<\/jats:p>","DOI":"10.3390\/pharmaceutics13121991","type":"journal-article","created":{"date-parts":[[2021,11,30]],"date-time":"2021-11-30T23:22:56Z","timestamp":1638314576000},"page":"1991","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Recent Advances in Therapeutic Drug Monitoring of Voriconazole, Mycophenolic Acid, and Vancomycin: A Literature Review of Pediatric Studies"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5495-8594","authenticated-orcid":false,"given":"Matylda","family":"Resztak","sequence":"first","affiliation":[{"name":"Department of Physical Pharmacy and Pharmacokinetics, Poznan University of Medical Sciences, 6 \u015awi\u0119cickiego Street, 60-781 Pozna\u0144, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2764-1575","authenticated-orcid":false,"given":"Joanna","family":"Sobiak","sequence":"additional","affiliation":[{"name":"Department of Physical Pharmacy and Pharmacokinetics, Poznan University of Medical Sciences, 6 \u015awi\u0119cickiego Street, 60-781 Pozna\u0144, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1581-8326","authenticated-orcid":false,"given":"Andrzej","family":"Czyrski","sequence":"additional","affiliation":[{"name":"Department of Physical Pharmacy and Pharmacokinetics, Poznan University of Medical Sciences, 6 \u015awi\u0119cickiego Street, 60-781 Pozna\u0144, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,11,23]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1128\/AAC.00751-08","article-title":"Population Pharmacokinetic Analysis of Voriconazole Plasma Concentration Data from Pediatric Studies","volume":"53","author":"Karlsson","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.ijantimicag.2016.11.028","article-title":"Dose optimisation of voriconazole with therapeutic drug monitoring in children: A single-centre experience in China","volume":"49","author":"Liu","year":"2017","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1128\/AAC.01540-12","article-title":"Highly Variable Plasma Concentrations of Voriconazole in Pediatric Hematopoietic Stem Cell Transplantation Patients","volume":"57","author":"Bartelink","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1007\/s40262-016-0379-2","article-title":"Pediatric Clinical Pharmacology of Voriconazole: Role of Pharmacokinetic\/Pharmacodynamic Modeling in Pharmacotherapy","volume":"55","author":"Kadam","year":"2016","journal-title":"Clin. Pharmacokinet."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1093\/mmy\/myz006","article-title":"Impact of dose adaptations following voriconazole therapeutic drug monitoring in pediatric patients","volume":"57","author":"Lempers","year":"2019","journal-title":"Med Mycol."},{"key":"ref_6","first-page":"955","article-title":"A phase I dose finding study of intravenous voriconazole in pediatric patients undergoing hematopoietic cell transplantation","volume":"55","author":"Jennissen","year":"2019","journal-title":"Bone Marrow Transplant."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"5497427","DOI":"10.1155\/2021\/5497427","article-title":"Determination of Voriconazole Plasma Concentration by HPLC Technique and Evaluating Its Association with Clinical Outcome and Adverse Effects in Patients with Invasive Aspergillosis","volume":"2021","author":"Yousefian","year":"2021","journal-title":"Can. J. Infect. Dis. Med Microbiol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jiac.2015.09.008","article-title":"Oral administration and younger age decrease plasma concentrations of voriconazole in pediatric patients","volume":"22","author":"Kato","year":"2016","journal-title":"J. Infect. Chemother."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"3165","DOI":"10.1128\/AAC.47.10.3165-3169.2003","article-title":"In Vivo Pharmacokinetics and Pharmacodynamics of a New Triazole, Voriconazole, in a Murine Candidiasis Model","volume":"47","author":"Andes","year":"2003","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1002\/phar.1631","article-title":"Pharmacokinetic and Pharmacodynamic Properties of Oral Voriconazole in Patients with Invasive Fungal Infections","volume":"35","author":"Wang","year":"2015","journal-title":"Pharmacother. J. Hum. Pharmacol. Drug Ther."},{"key":"ref_11","first-page":"700","article-title":"Voriconazole drug monitoring in the management of invasive fungal infection in immunocompromised children: A prospective study","volume":"67","author":"Frick","year":"2011","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e111582","DOI":"10.5812\/ijp.111582","article-title":"Voriconazole Therapeutic Drug Monitoring: How to Adjust the Dose in Pediatrics?","volume":"31","author":"Faghihi","year":"2021","journal-title":"Iran. J. Pediatr."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1080\/17425255.2019.1671971","article-title":"Therapeutic drug monitoring of systemic antifungal agents: A pragmatic approach for adult and pediatric patients","volume":"15","author":"John","year":"2019","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"5180","DOI":"10.1128\/AAC.01111-12","article-title":"Combination of Voriconazole and Anidulafungin for Treatment of Triazole-Resistant Aspergillus fumigatus in anIn VitroModel of Invasive Pulmonary Aspergillosis","volume":"56","author":"Jeans","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"4782","DOI":"10.1128\/AAC.01083-10","article-title":"Observational Study of the Clinical Efficacy of Voriconazole and Its Relationship to Plasma Concentrations in Patients","volume":"55","author":"Troke","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1093\/jac\/dkt508","article-title":"Therapeutic drug monitoring (TDM) of antifungal agents: Guidelines from the British Society for Medical Mycology","volume":"69","author":"Ashbee","year":"2013","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1002\/cpt.583","article-title":"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C19 and Voriconazole Therapy","volume":"102","author":"Moriyama","year":"2016","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1093\/jac\/dkw045","article-title":"Trough concentration of voriconazole and its relationship with efficacy and safety: A systematic review and meta-analysis","volume":"71","author":"Jin","year":"2016","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"4793","DOI":"10.1128\/AAC.00626-12","article-title":"Multicenter Study of Voriconazole Pharmacokinetics and Therapeutic Drug Monitoring","volume":"56","author":"Dolton","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"e00955-18","DOI":"10.1128\/AAC.00955-18","article-title":"Therapeutic Drug Monitoring of Voriconazole in Children from a Tertiary Care Center in China","volume":"62","author":"Hu","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1111\/jcpt.12817","article-title":"Impact of voriconazole plasma concentrations on treatment response in critically ill patients","volume":"44","author":"Ruiz","year":"2019","journal-title":"J. Clin. Pharm. Ther."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1093\/jac\/dkw099","article-title":"Utility of voriconazole therapeutic drug monitoring: A meta-analysis","volume":"71","author":"Luong","year":"2016","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.ijantimicag.2014.07.013","article-title":"Efficacy and safety of voriconazole and CYP2C19 polymorphism for optimised dosage regimens in patients with invasive fungal infections","volume":"44","author":"Wang","year":"2014","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1086\/648679","article-title":"Voriconazole Pharmacokinetics and Pharmacodynamics in Children","volume":"50","author":"Neely","year":"2010","journal-title":"Clin. Infect. Dis."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1002\/pbc.24262","article-title":"Importance of voriconazole therapeutic drug monitoring in pediatric cancer patients with invasive aspergillosis","volume":"60","author":"Choi","year":"2012","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"557","DOI":"10.3109\/08880018.2015.1088905","article-title":"The Clinical Significance of Voriconazole Therapeutic Drug Monitoring in Children With Invasive Fungal Infections","volume":"32","author":"Kang","year":"2015","journal-title":"Pediatr. Hematol. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.jiac.2020.11.014","article-title":"Optimal trough concentration of voriconazole with therapeutic drug monitoring in children: A systematic review and meta-analysis","volume":"27","author":"Hanai","year":"2020","journal-title":"J. Infect. Chemother."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s10096-010-1079-8","article-title":"Voriconazole plasma levels in children are highly variable","volume":"30","author":"Spriet","year":"2010","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1093\/jac\/dkw056","article-title":"Voriconazole dosing and therapeutic drug monitoring in children: Experience from a paediatric tertiary care centre","volume":"71","author":"Boast","year":"2016","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1111\/bcpt.13465","article-title":"Voriconazole therapeutic drug monitoring in critically ill patients improves efficacy and safety of antifungal therapy","volume":"127","author":"Li","year":"2020","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1097\/FTD.0b013e3182241b2b","article-title":"Therapeutic Drug Monitoring of Voriconazole After Intravenous Administration in Infants and Children With Primary Immunodeficiency","volume":"33","author":"Gerin","year":"2011","journal-title":"Ther. Drug Monit."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"3032","DOI":"10.1128\/AAC.05761-11","article-title":"Integrated Population Pharmacokinetic Analysis of Voriconazole in Children, Adolescents, and Adults","volume":"56","author":"Friberg","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1007\/s40262-014-0181-y","article-title":"A Physiologically Based Pharmacokinetic Model for Voriconazole Disposition Predicts Intestinal First-pass Metabolism in Children","volume":"53","author":"Zane","year":"2014","journal-title":"Clin. Pharmacokinet."},{"key":"ref_34","first-page":"17","article-title":"Voriconazole Monitoring in Children with Invasive Fungal Infections","volume":"20","author":"Tucker","year":"2015","journal-title":"J. Pediatr. Pharmacol. Ther."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1007\/s10156-012-0438-z","article-title":"A retrospective analysis of voriconazole pharmacokinetics in Japanese pediatric and adolescent patients","volume":"19","author":"Mori","year":"2013","journal-title":"J. Infect. Chemother."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1002\/phar.1829","article-title":"An Optimized Voriconazole Dosing Strategy to Achieve Therapeutic Serum Concentrations in Children Younger than 2 Years Old","volume":"36","author":"Zembles","year":"2016","journal-title":"Pharmacother. J. Hum. Pharmacol. Drug Ther."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1097\/FTD.0b013e31823f3516","article-title":"Therapeutic Drug Monitoring of Voriconazole in Children","volume":"34","author":"Chen","year":"2012","journal-title":"Ther. Drug Monit."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1097\/INF.0b013e31824acc33","article-title":"Therapeutic Monitoring of Voriconazole in Children Less Than Three Years of Age: A Case Report and Summary of Voriconazole Concentrations for Ten Children","volume":"31","author":"Doby","year":"2012","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1111\/bcp.13401","article-title":"Therapeutic drug monitoring of voriconazole for treatment and prophylaxis of invasive fungal infection in children: Voriconazole Therapeutic Drug Monitoring in Paediatrics","volume":"84","author":"Allegra","year":"2017","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_40","unstructured":"Zhao, Y.-C., Zou, Y., Tang, D., Xiao, C.-L., Xiao, Y.-W., Wang, F., Zhang, B.-K., Xiang, D.-X., Yu, F., and Yan, M. (2021, January 10). Possibly Appropriate Maintenance Dose of Voriconazole in Pediatric Patients: A Single Center Observational Study. Available online: https:\/\/assets.researchsquare.com\/files\/rs-222933\/v2\/ebdd07af-2ef9-46de-8730-235df3de207d.pdf?c=1631885086."},{"key":"ref_41","first-page":"26","article-title":"Characterization of Therapeutic Drug Monitoring Practices of Voriconazole and Posaconazole at a Pediatric Hospital","volume":"26","author":"Duehlmeyer","year":"2021","journal-title":"J. Pediatr. Pharmacol. Ther."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Valle-T-Figueras, J., Mir\u00f3, B.R., Carabante, M.B., D\u00edaz-De-Heredia, C., Bofarull, J.V., Mendoza-Palomar, N., Mart\u00edn-G\u00f3mez, M., and Soler-Palac\u00edn, P. (2021). Voriconazole Use in Children: Therapeutic Drug Monitoring and Control of Inflammation as Key Points for Optimal Treatment. J. Fungi, 7.","DOI":"10.3390\/jof7060456"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"e219","DOI":"10.1097\/MPH.0b013e3182880eaa","article-title":"Correlation of CYP2C19 Phenotype With Voriconazole Plasma Concentration in Children","volume":"35","author":"Narita","year":"2013","journal-title":"J. Pediatr. Hematol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1177\/1060028020948174","article-title":"Effect of Therapeutic Drug Monitoring and Cytochrome P450 2C19 Genotyping on Clinical Outcomes of Voriconazole: A Systematic Review","volume":"55","author":"Lee","year":"2020","journal-title":"Ann. Pharmacother."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s12281-020-00371-w","article-title":"Applying Pharmacogenomics to Antifungal Selection and Dosing: Are We There Yet?","volume":"14","author":"Miller","year":"2020","journal-title":"Curr. Fungal Infect. Rep."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1007\/s12281-015-0219-0","article-title":"Therapeutic Drug Monitoring and Genotypic Screening in the Clinical Use of Voriconazole","volume":"9","author":"Moriyama","year":"2015","journal-title":"Curr. Fungal Infect. Rep."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1002\/phar.1400","article-title":"CYP2C19 Polymorphisms and Therapeutic Drug Monitoring of Voriconazole: Are We Ready for Clinical Implementation of Pharmacogenomics?","volume":"34","author":"Obeng","year":"2014","journal-title":"Pharmacother. J. Hum. Pharmacol. Drug Ther."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1002\/cpt.1641","article-title":"Prospective CYP2C19-Guided Voriconazole Prophylaxis in Patients with Neutropenic Acute Myeloid Leukemia Reduces the Incidence of Subtherapeutic Antifungal Plasma Concentrations","volume":"107","author":"Hicks","year":"2019","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.bbmt.2015.11.011","article-title":"Genotype-Directed Dosing Leads to Optimized Voriconazole Levels in Pediatric Patients Receiving Hematopoietic Stem Cell Transplantation","volume":"22","author":"Teusink","year":"2015","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1080\/1120009X.2020.1765604","article-title":"Differential effects of C-reactive protein levels on voriconazole metabolism at three age groups in allogeneic hematopoietic cell transplant recipients","volume":"33","author":"Luo","year":"2020","journal-title":"J. Chemother."},{"key":"ref_51","first-page":"678","article-title":"The effect of inflammation on voriconazole trough concentrations in children: Letter to the Editor","volume":"83","author":"Veringa","year":"2016","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"6782","DOI":"10.1128\/AAC.03641-14","article-title":"Impact of Hypoalbuminemia on Voriconazole Pharmacokinetics in Critically Ill Adult Patients","volume":"58","author":"Vanstraelen","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"112952","DOI":"10.1016\/j.jpba.2019.112952","article-title":"Determination of total and free voriconazole in human plasma: Application to pharmacokinetic study and therapeutic monitoring","volume":"178","author":"Resztak","year":"2019","journal-title":"J. Pharm. Biomed. Anal."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"5780","DOI":"10.1128\/AAC.05010-11","article-title":"Comparison of Pharmacokinetics and Safety of Voriconazole Intravenous-to-Oral Switch in Immunocompromised Adolescents and Healthy Adults","volume":"55","author":"Driscoll","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1097\/INF.0b013e318204d227","article-title":"Impact of Therapeutic Drug Monitoring of Voriconazole in a Pediatric Population","volume":"30","author":"Verweij","year":"2011","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"2717","DOI":"10.1093\/jac\/dks258","article-title":"Monitoring of voriconazole plasma concentrations in immunocompromised paediatric patients","volume":"67","author":"Pieper","year":"2012","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Zhao, Y., Hou, J., Xiao, Y., Wang, F., Zhang, B., Zhang, M., Jiang, Y., Li, J., Gong, G., and Xiang, D. (2021). Predictors of Voriconazole Trough Concentrations in Patients with Child\u2013Pugh Class C Cirrhosis: A Prospective Study. Antibiotics, 10.","DOI":"10.3390\/antibiotics10091130"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ijid.2018.05.009","article-title":"Therapeutic drug monitoring and safety of voriconazole therapy in patients with Child\u2013Pugh class B and C cirrhosis: A multicenter study","volume":"72","author":"Wang","year":"2018","journal-title":"Int. J. Infect. Dis."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.ijid.2020.02.041","article-title":"Pharmacokinetics of intravenous voriconazole in patients with liver dysfunction: A prospective study in the intensive care unit","volume":"93","author":"Lin","year":"2020","journal-title":"Int. J. Infect. Dis."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1080\/00365513.2020.1868048","article-title":"Correlation between enzyme multiplied immunoassay technique and high-performance liquid chromatography in the quantification of voriconazole in a paediatric population","volume":"81","author":"Li","year":"2021","journal-title":"Scand. J. Clin. Lab. Investig."},{"key":"ref_61","first-page":"1","article-title":"Determination of voriconazole in human plasma by liquid chromatography-tandem mass spectrometry and its application in therapeutic drug monitoring in Chinese patients","volume":"48","author":"Mei","year":"2019","journal-title":"J. Int. Med Res."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1093\/jac\/dks285","article-title":"Development and validation of a new method to simultaneously quantify triazoles in plasma spotted on dry sample spot devices and analysed by HPLC-MS","volume":"67","author":"Baietto","year":"2012","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_63","first-page":"e45645","article-title":"Therapeutic Drug Monitoring of Voriconazole: Comparison of Bioassay with High-Performance Liquid Chromatography","volume":"10","author":"Badiee","year":"2017","journal-title":"Jundishapur J. Microbiol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1517\/17425255.2016.1170806","article-title":"Therapeutic drug monitoring of mycophenolate in adult solid organ transplant patients: An update","volume":"12","author":"Kiang","year":"2016","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"e13997","DOI":"10.1111\/ctr.13997","article-title":"A short overview on mycophenolic acid pharmacology and pharmacokinetics","volume":"34","author":"Ferreira","year":"2020","journal-title":"Clin. Transplant."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1097\/FTD.0000000000000363","article-title":"Pharmacokinetics of Mycophenolic Acid and Dose Optimization in Children After Intestinal Transplantation","volume":"39","author":"Barau","year":"2017","journal-title":"Ther. Drug Monit."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1111\/petr.12695","article-title":"Pharmacokinetics and target attainment of mycophenolate in pediatric renal transplant patients","volume":"20","author":"Martial","year":"2016","journal-title":"Pediatr. Transplant."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1097\/FTD.0000000000000403","article-title":"A Retrospective Study on Mycophenolic Acid Drug Interactions: Effect of Prednisone, Sirolimus, and Tacrolimus With MPA","volume":"39","author":"Yoo","year":"2017","journal-title":"Ther. Drug Monit."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.2215\/CJN.00320116","article-title":"Mycophenolic Acid Pharmacokinetics and Relapse in Children with Steroid\u2013Dependent Idiopathic Nephrotic Syndrome","volume":"11","author":"Tellier","year":"2016","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1681\/ASN.2012121200","article-title":"Mycophenolate Mofetil versus Cyclosporin A in Children with Frequently Relapsing Nephrotic Syndrome","volume":"24","author":"Gellermann","year":"2013","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1111\/bcp.12392","article-title":"Pharmacokinetics of mycophenolate mofetil in children with lupus and clinical findings in favour of therapeutic drug monitoring","volume":"78","author":"Woillard","year":"2014","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1002\/lt.22364","article-title":"Optimization of the dosing regimen of mycophenolate mofetil in pediatric liver transplant recipients","volume":"17","author":"Barau","year":"2011","journal-title":"Liver Transplant."},{"key":"ref_73","first-page":"341","article-title":"Mycophenolic acid area under the concentration-time curve is associated with therapeutic response in childhood-onset lupus nephritis","volume":"36","author":"Woillard","year":"2020","journal-title":"Pediatr. Nephrol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"653525","DOI":"10.3389\/fphar.2021.653525","article-title":"CYP3A5 and UGT1A9 Polymorphisms Influence Immunosuppressive Therapy in Pediatric Kidney Transplant Recipients","volume":"12","author":"Krall","year":"2021","journal-title":"Front. Pharmacol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"e13355","DOI":"10.1111\/petr.13355","article-title":"RELATE: Relationship of limited sampling strategy and adverse effects of mycophenolate mofetil in pediatric renal transplant patients","volume":"23","author":"Berger","year":"2019","journal-title":"Pediatr. Transplant."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1097\/FTD.0000000000000081","article-title":"Effects of Unbound Mycophenolic Acid on Inosine Monophosphate Dehydrogenase Inhibition in Pediatric Kidney Transplant Patients","volume":"36","author":"Smits","year":"2014","journal-title":"Ther. Drug Monit."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1097\/FTD.0000000000000361","article-title":"Single-Nucleotide Polymorphism of CYP3A5 Impacts the Exposure to Tacrolimus in Pediatric Renal Transplant Recipients: A Pharmacogenetic Substudy of the TWIST Trial","volume":"39","author":"Billing","year":"2017","journal-title":"Ther. Drug Monit."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1111\/bcp.13911","article-title":"A multiple methods approach to determine adherence with prescribed mycophenolate in children with kidney transplant","volume":"85","author":"Almardini","year":"2019","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1111\/bcp.12426","article-title":"Population pharmacokinetic\u2212pharmacodynamic modelling of mycophenolic acid in paediatric renal transplant recipients in the early post-transplant period","volume":"78","author":"Dong","year":"2014","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1177\/0091270010368542","article-title":"Inosine Monophosphate Dehydrogenase (IMPDH) Activity as a Pharmacodynamic Biomarker of Mycophenolic Acid Effects in Pediatric Kidney Transplant Recipients","volume":"51","author":"Fukuda","year":"2011","journal-title":"J. Clin. Pharmacol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1097\/FTD.0b013e3182708f84","article-title":"UGT1A9, UGT2B7, and MRP2 Genotypes Can Predict Mycophenolic Acid Pharmacokinetic Variability in Pediatric Kidney Transplant Recipients","volume":"34","author":"Fukuda","year":"2012","journal-title":"Ther. Drug Monit."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1111\/petr.12542","article-title":"The effect of MMF dose and trough levels on adverse effects in pediatric heart transplant recipients","volume":"19","author":"Siddiqi","year":"2015","journal-title":"Pediatr. Transplant."},{"key":"ref_83","first-page":"16","article-title":"Multi-institutional Study of Outcomes After Pediatric Heart Transplantation: Candidate Gene Polymorphism Analysis of ABCC2","volume":"19","author":"Burckart","year":"2014","journal-title":"J. Pediatr. Pharmacol. Ther."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"e27091","DOI":"10.1002\/pbc.27091","article-title":"Mycophenolate mofetil administered every 8 hours in combination with tacrolimus is efficacious in the prophylaxis of acute graft versus host disease in childhood, adolescent, and young adult allogeneic stem cell transplantation recipients","volume":"65","author":"Militano","year":"2018","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1002\/jcph.745","article-title":"Pharmacokinetic Variability of Mycophenolic Acid in Pediatric and Adult Patients With Hematopoietic Stem Cell Transplantation","volume":"56","author":"Zhang","year":"2016","journal-title":"J. Clin. Pharmacol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1111\/petr.12545","article-title":"Mycophenolate mofetil for treatment of steroid-refractory acute graft-versus-host disease after pediatric hematopoietic stem cell transplantation","volume":"19","author":"Inagaki","year":"2015","journal-title":"Pediatr. Transplant."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.bbmt.2015.12.013","article-title":"A Pilot Study of Continuous Infusion of Mycophenolate Mofetil for Prophylaxis of Graft-versus-Host-Disease in Pediatric Patients","volume":"22","author":"Windreich","year":"2015","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_88","doi-asserted-by":"crossref","unstructured":"Carlone, G., Simeone, R., Baraldo, M., Maestro, A., Zanon, D., Barbi, E., and Maximova, N. (2021). Area-Under-the-Curve-Based Mycophenolate Mofetil Dosage May Contribute to Decrease the Incidence of Graft-versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation in Pediatric Patients. J. Clin. Med., 10.","DOI":"10.3390\/jcm10030406"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1177\/0091270011422814","article-title":"Population pharmacokinetics of unbound mycophenolic acid in pediatric and young adult patients undergoing allogeneic hematopoietic cell transplantation","volume":"52","author":"Kim","year":"2012","journal-title":"J. Clin. Pharmacol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1016\/j.bbmt.2015.01.024","article-title":"Intensified Mycophenolate Mofetil Dosing and Higher Mycophenolic Acid Trough Levels Reduce Severe Acute Graft-versus-Host Disease after Double-Unit Cord Blood Transplantation","volume":"21","author":"Harnicar","year":"2015","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1097\/RHU.0000000000000357","article-title":"Use of Glucuronidated Mycophenolic Acid Levels for Therapeutic Monitoring in Pediatric Lupus Nephritis Patients","volume":"22","author":"Tran","year":"2016","journal-title":"J. Clin. Rheumatol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.3389\/fphar.2020.605060","article-title":"PK\/PD Study of Mycophenolate Mofetil in Children With Systemic Lupus Erythematosus to Inform Model-Based Precision Dosing","volume":"11","author":"Chen","year":"2020","journal-title":"Front. Pharmacol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.semarthrit.2010.05.007","article-title":"Pharmacokinetics and Pharmacodynamics of Mycophenolic Acid and Their Relation to Response to Therapy of Childhood-Onset Systemic Lupus Erythematosus","volume":"40","author":"Fukuda","year":"2011","journal-title":"Semin. Arthritis Rheum."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1007\/s40744-021-00324-w","article-title":"Mycophenolic Acid Exposure Optimization Based on Vitamin D Status in Children with Systemic Lupus Erythematosus: A Single-Center Retrospective Study","volume":"8","author":"Ye","year":"2021","journal-title":"Rheumatol. Ther."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1097\/FTD.0b013e318228195f","article-title":"Nonsteroidal Anti-Inflammatory Drugs May Reduce Enterohepatic Recirculation of Mycophenolic Acid in Patients With Childhood-Onset Systemic Lupus Erythematosus","volume":"33","author":"Fukuda","year":"2011","journal-title":"Ther. Drug Monit."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1177\/09612033211034555","article-title":"Exposure levels of mycophenolic acid are associated with comorbidities in children with systemic lupus erythematosus","volume":"30","author":"Ye","year":"2021","journal-title":"Lupus"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.ejps.2015.06.017","article-title":"Monitoring of mycophenolate mofetil metabolites in children with nephrotic syndrome and the proposed novel target values of pharmacokinetic parameters","volume":"77","author":"Sobiak","year":"2015","journal-title":"Eur. J. Pharm. Sci."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1097\/FTD.0000000000000671","article-title":"Generation and Validation of a Limited Sampling Strategy to Monitor Mycophenolic Acid Exposure in Children With Nephrotic Syndrome","volume":"41","author":"Benz","year":"2019","journal-title":"Ther. Drug Monit."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"162","DOI":"10.5414\/CN109583","article-title":"Nephrotic state substantially enhances apparent mycophenolic acid clearance","volume":"91","author":"Kirpalani","year":"2019","journal-title":"Clin. Nephrol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1007\/s10157-016-1267-7","article-title":"Pharmacokinetics of mycophenolic acid in children with clinically stable idiopathic nephrotic syndrome receiving cyclosporine","volume":"21","author":"Hibino","year":"2016","journal-title":"Clin. Exp. Nephrol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s00467-011-2006-7","article-title":"Mycophenolate mofetil for steroid-dependent nephrotic syndrome: A phase II Bayesian trial","volume":"27","author":"Baudouin","year":"2011","journal-title":"Pediatr. Nephrol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1097\/FTD.0000000000000258","article-title":"Mycophenolate Mofetil Therapy in Children With Idiopathic Nephrotic Syndrome: Does Therapeutic Drug Monitoring Make a Difference?","volume":"38","author":"Hackl","year":"2016","journal-title":"Ther. Drug Monit."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.phrs.2011.01.009","article-title":"Development of a Bayesian estimator for the therapeutic drug monitoring of mycophenolate mofetil in children with idiopathic nephrotic syndrome","volume":"63","author":"Guigonis","year":"2011","journal-title":"Pharmacol. Res."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1093\/ndt\/gfr572","article-title":"Sequential maintenance therapy with cyclosporin A and mycophenolate mofetil for sustained remission of childhood steroid-resistant nephrotic syndrome","volume":"27","author":"Gellermann","year":"2011","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1007\/s00228-019-02701-5","article-title":"Limited sampling strategy to predict mycophenolic acid area under the curve in pediatric patients with nephrotic syndrome: A retrospective cohort study","volume":"75","author":"Sobiak","year":"2019","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1159\/000445070","article-title":"The Value of Monitoring the Serum Concentration of Mycophenolate Mofetil in Children with Steroid-Dependent\/Frequent Relapsing Nephrotic Syndrome","volume":"132","author":"Tong","year":"2016","journal-title":"Nephron"},{"key":"ref_107","doi-asserted-by":"crossref","unstructured":"Sobiak, J., J\u00f3\u017awiak, A., Wzi\u0119tek, H., Zachwieja, J., and Ostalska-Nowicka, D. (2020). The Application of Inosine 5\u2032-Monophosphate Dehydrogenase Activity Determination in Peripheral Blood Mononuclear Cells for Monitoring Mycophenolate Mofetil Therapy in Children with Nephrotic Syndrome. Pharmaceuticals, 13.","DOI":"10.3390\/ph13080200"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1007\/s00467-017-3846-6","article-title":"Mycophenolate mofetil following glucocorticoid treatment in Henoch-Sch\u00f6nlein purpura nephritis: The role of early initiation and therapeutic drug monitoring","volume":"33","author":"Hackl","year":"2017","journal-title":"Pediatr. Nephrol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1080\/14397595.2018.1532785","article-title":"Pharmacokinetics of mycophenolate mofetil in juvenile patients with autoimmune diseases","volume":"29","author":"Nakaseko","year":"2019","journal-title":"Mod. Rheumatol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2165\/00003088-200746010-00002","article-title":"Clinical Pharmacokinetics and Pharmacodynamics of Mycophenolate in Solid Organ Transplant Recipients","volume":"46","author":"Staatz","year":"2007","journal-title":"Clin. Pharmacokinet."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1191\/0961203305LU2109OA","article-title":"Mechanisms of action of mycophenolate mofetil","volume":"14","author":"Allison","year":"2005","journal-title":"Lupus"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1111\/petr.12559","article-title":"What is the intrapatient variability of mycophenolic acid trough levels?","volume":"19","author":"Todorova","year":"2015","journal-title":"Pediatr. Transplant."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1007\/s13318-021-00713-0","article-title":"A Systematic Review of Multiple Linear Regression-Based Limited Sampling Strategies for Mycophenolic Acid Area Under the Concentration\u2013Time Curve Estimation","volume":"46","author":"Sobiak","year":"2021","journal-title":"Eur. J. Drug Metab. Pharmacokinet."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1111\/petr.12637","article-title":"Minimum mycophenolic acid levels are associated with donor-specific antibody formation","volume":"20","author":"Filler","year":"2015","journal-title":"Pediatr. Transplant."},{"key":"ref_115","first-page":"513","article-title":"Cyclosporine versus mycophenolate mofetil for maintenance of remission of steroid-dependent nephrotic syndrome after a single infusion of rituximab","volume":"172","author":"Fujinaga","year":"2012","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"e4989","DOI":"10.1002\/bmc.4989","article-title":"Validated LC\u2013MS\/MS method for quantitation of total and free mycophenolic acid concentration and its application to a pharmacokinetic study in pediatric renal transplant recipients","volume":"35","author":"Liu","year":"2020","journal-title":"Biomed. Chromatogr."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1007\/s00228-011-1203-4","article-title":"Inosine monophosphate dehydrogenase activity in paediatrics: Age-related regulation and response to mycophenolic acid","volume":"68","author":"Rother","year":"2012","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1097\/FTD.0b013e31816ba73a","article-title":"Pharmacokinetics of Mycophenolate Mofetil and Sirolimus in Children","volume":"30","author":"Filler","year":"2008","journal-title":"Ther. Drug Monit."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1007\/s00467-015-3303-3","article-title":"Developmental changes of MPA exposure in children","volume":"31","author":"Yoo","year":"2016","journal-title":"Pediatr. Nephrol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1097\/00007691-200412000-00005","article-title":"Comparison of Liquid Chromatography-Tandem Mass Spectrometry with a Commercial Enzyme-Multiplied Immunoassay for the Determination of Plasma MPA in Renal Transplant Recipients and Consequences for Therapeutic Drug Monitoring","volume":"26","author":"Rousseau","year":"2004","journal-title":"Ther. Drug Monit."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1097\/FTD.0000000000000151","article-title":"A Comparison of the Immunochemical Methods, PETINIA and EMIT, With That of HPLC-UV for the Routine Monitoring of Mycophenolic Acid in Heart Transplant Patients","volume":"37","author":"Kunicki","year":"2015","journal-title":"Ther. Drug Monit."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1002\/bdd.2206","article-title":"The development of a population physiologically based pharmacokinetic model for mycophenolic mofetil and mycophenolic acid in humans using data from plasma, saliva, and kidney tissue","volume":"40","author":"Alsmadi","year":"2019","journal-title":"Biopharm. Drug Dispos."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.chroma.2012.04.008","article-title":"Liquid chromatography\u2013tandem mass spectrometry method for the quantification of mycophenolic acid and its phenolic glucuronide in saliva and plasma using a standardized saliva collection device","volume":"1241","author":"Wiesen","year":"2012","journal-title":"J. Chromatogr. A"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1111\/petr.12311","article-title":"Bioavailability of a generic of the immunosuppressive agent mycophenolate mofetil in pediatric patients","volume":"18","author":"Villa","year":"2014","journal-title":"Pediatr. Transplant."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1093\/jpids\/piz036","article-title":"Intravenous Vancomycin Therapeutic Drug Monitoring in Children: Evaluation of a Pharmacy-Driven Protocol and Collaborative Practice Agreement","volume":"9","author":"Olson","year":"2019","journal-title":"J. Pediatr. Infect. Dis. Soc."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s40272-018-0282-4","article-title":"The Relationship Between Vancomycin Trough Concentrations and AUC\/MIC Ratios in Pediatric Patients: A Qualitative Systematic Review","volume":"20","author":"Tkachuk","year":"2018","journal-title":"Pediatr. Drugs"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1086\/600877","article-title":"Vancomycin Therapeutic Guidelines: A Summary of Consensus Recommendations from the Infectious Diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists","volume":"49","author":"Rybak","year":"2009","journal-title":"Clin. Infect. Dis."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s40272-019-00328-8","article-title":"Vancomycin Prescribing and Therapeutic Drug Monitoring in Children With and Without Acute Kidney Injury After Cardiac Arrest","volume":"21","author":"Fitzgerald","year":"2019","journal-title":"Pediatr. Drugs"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"82","DOI":"10.2146\/ajhp080434","article-title":"Therapeutic monitoring of vancomycin in adult patients: A consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists","volume":"66","author":"Rybak","year":"2009","journal-title":"Am. J. Heal. Pharm."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1093\/cid\/ciq146","article-title":"Clinical Practice Guidelines by the Infectious Diseases Society of America for the Treatment of Methicillin-Resistant Staphylococcus aureus Infections in Adults and Children","volume":"52","author":"Liu","year":"2011","journal-title":"Clin. Infect. Dis."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1097\/INF.0b013e318299f75c","article-title":"Desired Vancomycin Trough Serum Concentration for Treating Invasive Methicillin-resistant Staphylococcal Infections","volume":"32","author":"Frymoyer","year":"2013","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"e155","DOI":"10.1097\/INF.0b013e318286378e","article-title":"Improved Vancomycin Dosing in Children Using Area Under the Curve Exposure","volume":"32","author":"Le","year":"2013","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/j.jiac.2021.01.015","article-title":"The optimal trough-guided monitoring of vancomycin in children: Systematic review and meta-analyses","volume":"27","author":"Moriyama","year":"2021","journal-title":"J. Infect. Chemother."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1097\/INF.0000000000001882","article-title":"Nephrotoxicity With Vancomycin in the Pediatric Population: A Systematic Review and Meta-Analysis","volume":"37","author":"Fiorito","year":"2018","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1097\/FTD.0000000000000190","article-title":"Evaluation of Target Attainment of Vancomycin Area Under the Curve in Children With Methicillin-Resistant Staphylococcus Aureus Bacteremia","volume":"37","author":"Hahn","year":"2015","journal-title":"Ther. Drug Monit."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.ijantimicag.2013.11.006","article-title":"Dose optimisation of antibiotics in children: Application of pharmacokinetics\/pharmacodynamics in paediatrics","volume":"43","author":"Downes","year":"2013","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_137","unstructured":"(2021, October 26). Dosing and Monitoring of Vancomycin in Pediatric Patients. Available online: https:\/\/Www.Med.Umich.Edu\/Asp\/Pdf\/Pk\/Vancomycin_Peds.Pdf."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1542\/hpeds.2019-0287","article-title":"Vancomycin Dosing in Children With Overweight or Obesity: A Systematic Review and Meta-analysis","volume":"10","author":"Khare","year":"2020","journal-title":"Hosp. Pediatr."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"4277","DOI":"10.1128\/AAC.01674-10","article-title":"Refining Vancomycin Protein Binding Estimates: Identification of Clinical Factors That Influence Protein Binding","volume":"55","author":"Butterfield","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.ijantimicag.2009.08.005","article-title":"Correlation between free and total vancomycin serum concentrations in patients treated for Gram-positive infections","volume":"34","author":"Berthoin","year":"2009","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"7073","DOI":"10.1128\/AAC.01185-15","article-title":"Factors Impacting Unbound Vancomycin Concentrations in Different Patient Populations","volume":"59","author":"Oyaert","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1097\/FTD.0000000000000122","article-title":"Measuring Unbound Versus Total Vancomycin Concentrations in Serum and Plasma: Methodological Issues and Relevance","volume":"37","author":"Stove","year":"2015","journal-title":"Ther. Drug Monit."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1136\/adc.88.5.419","article-title":"Hypoalbuminaemia in critically ill children: Incidence, prognosis, and influence on the anion gap","volume":"88","author":"Durward","year":"2003","journal-title":"Arch. Dis. Child."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/1056-8719(92)90066-A","article-title":"The influence of vancomycin concentration and the pH of plasma on vancomycin protein binding","volume":"28","author":"Chen","year":"1992","journal-title":"J. Pharmacol. Toxicol. Methods"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1002\/jcph.175","article-title":"Unbound fraction of vancomycin in intensive care unit patients","volume":"54","author":"Kees","year":"2013","journal-title":"J. Clin. Pharmacol."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"e12212","DOI":"10.1111\/jspn.12212","article-title":"Therapeutic antibiotic serum concentrations by two blood collection methods within the pediatric patient: A comparative effectiveness trial","volume":"23","author":"Lichliter","year":"2018","journal-title":"J. Sp\u00e9c. Pediatr. Nurs."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.jpeds.2010.08.019","article-title":"Incidence and Risk Factors Influencing the Development of Vancomycin Nephrotoxicity in Children","volume":"158","author":"McKamy","year":"2011","journal-title":"J. Pediatr."},{"key":"ref_148","first-page":"801","article-title":"Impact of vancomycin protein binding on target attainment in critically ill children: Back to the drawing board?","volume":"72","author":"Desmet","year":"2016","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"e250","DOI":"10.1097\/PCC.0b013e3181fe4047","article-title":"Vancomycin pharmacokinetic\u2013pharmacodynamic parameters to optimize dosage administration in critically ill children","volume":"12","author":"Giachetto","year":"2011","journal-title":"Pediatr. Crit. Care Med."},{"key":"ref_150","first-page":"423","article-title":"Effect of Vancomycin Loading Doses on the Attainment of Target Trough Concentrations in Hospitalized Children","volume":"25","author":"Dolan","year":"2020","journal-title":"J. Pediatr. Pharmacol. Ther."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1007\/s00228-017-2306-3","article-title":"Determining the optimal vancomycin daily dose for pediatrics: A meta-analysis","volume":"73","author":"Frade","year":"2017","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_152","unstructured":"(2021, June 30). Vancomycin Dosing and Pharmacokinetics in Postoperative Pediatric Cardiothoracic Surgery Patients, Available online: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC4778698."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"E6","DOI":"10.1111\/chd.12187","article-title":"Vancomycin-Associated Acute Kidney Injury in Pediatric Cardiac Intensive Care Patients","volume":"10","author":"Moffett","year":"2014","journal-title":"Congenit. Hear. Dis."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1002\/phar.1227","article-title":"Nephrotoxicity in Patients with Vancomycin Trough Concentrations of 15-20 \u03bcg\/ml in a Pediatric Intensive Care Unit","volume":"33","author":"Cies","year":"2013","journal-title":"Pharmacother. J. Hum. Pharmacol. Drug Ther."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1177\/0897190019829652","article-title":"Vancomycin-Associated Acute Kidney Injury in Critically Ill Adolescent and Young Adult Patients","volume":"33","author":"Hays","year":"2019","journal-title":"J. Pharm. Pr."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/jcph.782","article-title":"AUC-Guided Vancomycin Dosing in Adolescent Patients With Suspected Sepsis","volume":"57","author":"Lanke","year":"2016","journal-title":"J. Clin. Pharmacol."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.jcrc.2017.03.023","article-title":"Sepsis-associated in-hospital cardiac arrest: Epidemiology, pathophysiology, and potential therapies","volume":"40","author":"Morgan","year":"2017","journal-title":"J. Crit. Care"},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"e290","DOI":"10.1097\/PCC.0000000000001198","article-title":"A Population Pharmacokinetic Analysis to Study the Effect of Therapeutic Hypothermia on Vancomycin Disposition in Children Resuscitated From Cardiac Arrest","volume":"18","author":"Zane","year":"2017","journal-title":"Pediatr. Crit. Care Med."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"173580","DOI":"10.1016\/j.ejphar.2020.173580","article-title":"Therapeutic potential and molecular mechanisms of mycophenolic acid as an anticancer agent","volume":"887","author":"Benjanuwattra","year":"2020","journal-title":"Eur. J. Pharmacol."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1097\/FTD.0000000000000871","article-title":"Personalized Therapy for Mycophenolate: Consensus Report by the International Association of Therapeutic Drug Monitoring and Clinical Toxicology","volume":"43","author":"Bergan","year":"2021","journal-title":"Ther. Drug Monit."}],"container-title":["Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4923\/13\/12\/1991\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:34:49Z","timestamp":1760168089000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4923\/13\/12\/1991"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,23]]},"references-count":160,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["pharmaceutics13121991"],"URL":"https:\/\/doi.org\/10.3390\/pharmaceutics13121991","relation":{},"ISSN":["1999-4923"],"issn-type":[{"value":"1999-4923","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,23]]}}}